PROCEPT BIOROBOTICS CORPORATION

(PRCT)
  Report
Real-time Estimate Cboe BZX  -  01:41 2022-08-18 pm EDT
42.47 USD   -5.75%
08/05PROCEPT BIOROBOTICS CORP MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
AQ
08/05Goldman Sachs Adjusts Price Target for PROCEPT BioRobotics to $39 From $36, Maintains Neutral Rating
MT
08/04PROCEPT BIOROBOTICS : Second Quarter 2022 Earnings Call
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

PROCEPT BioRobotics Corporation : Technically solid

07/01/2022 | 03:40am EDT
long trade
Target price hit
Entry price : 32.17$ | Target : 43$ | Stop-loss : 24.9$ | Potential : 33.66%
Shares in PROCEPT BioRobotics Corporation do not show any sign of a slowdown in the ascending dynamic. Investors could bet on a continuation of the underlying trend.
Investors have an opportunity to buy the stock and target the $ 43.
PROCEPT BioRobotics Corporation : PROCEPT BioRobotics Corporation : Technically solid
Summary
  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths
  • The prospective high growth for the next fiscal years is among the main assets of the company
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.

Weaknesses
  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • The company has insufficient levels of profitability.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • The average consensus view of analysts covering the stock has deteriorated over the past four months.
  • Over the past twelve months, analysts' consensus has been significantly revised downwards.

© MarketScreener.com 2022

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Financials (USD)
Sales 2022 67,2 M - -
Net income 2022 -81,2 M - -
Net cash 2022 184 M - -
P/E ratio 2022 -24,6x
Yield 2022 -
Capitalization 2 009 M 2 009 M -
EV / Sales 2022 27,2x
EV / Sales 2023 16,4x
Nbr of Employees 234
Free-Float 96,7%
Upcoming event on PROCEPT BIOROBOTICS CORPORATION
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 45,06 $
Average target price 47,00 $
Spread / Average Target 4,31%
EPS Revisions
Managers and Directors
Reza Zadno President, Chief Executive Officer & Director
Kevin Waters Chief Financial Officer & Executive Vice President
Frederic H. Moll Chairman
Barry Templin Vice President-Clinical Affairs
Thomas J. Yorkey Senior VP-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
PROCEPT BIOROBOTICS CORPORATION80.17%2 009
ABBOTT LABORATORIES-21.45%193 597
MEDTRONIC PLC-8.26%126 108
BECTON, DICKINSON AND COMPANY7.51%75 357
HOYA CORPORATION-11.46%39 823
SARTORIUS STEDIM BIOTECH-17.41%37 347